NCT06099119View on ClinicalTrials.gov

Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Unresectable Pancreatic Cancer
Interventions
DRUG

creon 35.000 Ph.U (R)

Experimental arm: Pancreatic Exocrine Replacement Therapy (PERT) treatment during the six months study period.

OTHER

Best Standarard of Care

Control arm: no treatment over 3 months from randomization. PERT from third month untill last visit in sixt month

Trial Locations (4)

15706

RECRUITING

University Hospital of Santiago de Compostela, Santiago de Compostela

17177

NOT_YET_RECRUITING

Karolinska Institutet, Stockholm

20132

RECRUITING

Istituto di Ricovero e Cura Carattere Scientifico San Raffaele, Milan

31008

RECRUITING

Hospital Universitario de Navarra, Pamplona

All Listed Sponsors
collaborator

Complejo Hospitalario de Navarra

OTHER

collaborator

Karolinska Institutet

OTHER

collaborator

San Raffaele University Hospital, Italy

OTHER

collaborator

Beaujon Hospital

OTHER

lead

Hospital Clinico Universitario de Santiago

OTHER